Allarity Therapeutics, Inc.
Allarity Therapeutics Expands Phase 2 Stenoparib Trial to Three Ovarian Cancer Patient Cohorts
Investigator-supported move capitalizes on strong enrollment momentum and encouraging early clinical observations
Company newsroom
NASDAQ:ALLR
1 releases
Investigator-supported move capitalizes on strong enrollment momentum and encouraging early clinical observations